Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Prophylaxis of invasive fungal infections Age: Adult |
Dose: Delayed-release tablet – 300 mg Frequency: twice daily on the 1st day, then once daily thereafter Note: Treatment duration is based on recovery from neutropenia or immunosuppression |
|
Indication: Prophylaxis of invasive fungal infections Age: Adult |
Dose: Oral suspension – 200 mg Frequency: three times daily Note: Treatment duration is based on recovery from neutropenia or immunosuppression |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Invasive Aspergillus and Candida Infections Age: less than 18 years Condition: severely immunocompromised |
Dose: Intravenous – Dose not established Note: Safety and efficacy not established |
|
Indication: Invasive Aspergillus and Candida Infections Age: less than 13 years Condition: severely immunocompromised |
Dose: Tablet and Oral suspension – Dose not established Note: Safety and efficacy not established |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Moderate-to-severe renal impairment (estimated glomerular filtration rate less than 50 mL/min) |
Dose: Intravenous – Dose not specified Note: Avoid intravenous administration unless benefit/risk assessment justifies use. Accumulation of the intravenous vehicle, SBECD, is expected to occur. Serum creatinine levels should be closely monitored; if increases occur, consideration should be given to changing to oral posaconazole therapy. |
|
Condition: Severe renal impairment |
Dose: Tablets or Oral suspension – Dose not specified Note: Variability of systemic exposure with tablets or oral suspension observed. Monitored closely for breakthrough fungal infections. |
Administration
- Tablets: Take with food
- Oral suspension: Take with meal or nutritional supplement
Side Effect
- Fever (45%)
- Diarrhea (42%)
- Nausea (38%)
- Hypokalemia (30%)
- Headache (28%)
- Abd pain (27%)
- Anemia (25%)
- Cough (24%)
- Nausea (38%)
- Thrombocytopenia (29%)
- Constipation (21%)
- Dyspnea (20%)
- Febrile neutropenia (20%)
- Rigors (20%)
- Rash (19%)
- Bacteremia (18%)
- HTN (18%)
- Hypomagnesemia (18%)
- Fatigue (17%)
- Insomnia (17%)
- Mucositis (17%)
- Musculoskeletal pain (16%)
- Anorexia (15%)
- Herpes simplex (15%)
- Leg edema (15%)
- CMV infection (14%)
- Epistaxis (14%)
- Hypotension (14%)
- Pharyngitis (12%)
- Arthralgia (11%)
- Dizziness (11%)
- Hypoglycemia (11%)
- Petechiae (11%)
- Pruritus (11%)
- Back pain (10%)
- Dyspepsia (10%)
- Vaginal hemorrhage (10%)
- Anxiety (9%)
- Edema (9%)
- Hypocalcemia (9%)
- Weakness (8%)
- URI (7%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Efavirenz, fosamprenavir, cimetidine, esomeprazole, metoclopramide, phenytoin, rifabutin
|
Decreased plasma concentrations
|
|
Ritonavir, atazanavir
|
May increase plasma concentration
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Hypersensitivity
|
Risk of severe allergic reaction
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store below 25°C. Keep out of the reach of children.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.